

Code No: IP32D/R13

M. Pharmacy II Semester Regular/ Supplementary Examinations, July-2016

DRUG REGULATORY AFFAIRS

(Common to All Branches)

Time: 3 Hours

Max. Marks: 60

*Answer any FIVE Questions
All Questions Carry Equal Marks*

- | | | | |
|----|---|---|---|
| 1. | a | What are the reasons for conducting pre-formulation studies? | 4 |
| | b | Explain pre-formulation studies for semi-solid dosage forms. | 8 |
| 2. | a | Bring out the salient differences between Indian and US laws regulating to Patent approval process | 8 |
| | b | Define Intellectual Property Rights and explain different types. | 4 |
| 3. | a | Define clinical trial. Explain different phases of clinical trials. | 6 |
| | b | Explain statistical analysis of clinical data. | 6 |
| 4. | a | Explain stability testing of drug substances as per Indian regulatory requirements. | 6 |
| | b | Explain analytical method validation parameters in detail. | 6 |
| 5. | a | Discuss the biopharmaceutical considerations from the point of view of formulation and manufacturing process. | 8 |
| | b | Write note on pharmacokinetic validation. | 4 |
| 6. | a | What are regulatory guidelines for packing materials? | 6 |
| | b | Explain how evaluation of closures will be done as per Indian regulatory authorities. | 6 |
| 7. | a | What are regulatory requirements as per Indian regulatory authorities for manufacturing process of active ingredients | 6 |
| | b | Discuss current guidelines and developments as per regulatory requirements of European community for clinical bioavailability | 6 |
| 8. | a | Discuss regulatory guidelines as per US on clinical study design and documentation. | 8 |
| | b | Explain the essential drug regulatory guidelines in the pre-formulation studies of Ocular preparations. | 4 |
